What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review.
about
Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implicationsRheumatoid arthritis treatment: the earlier the better to prevent joint damageAnalysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis.High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort.Comparative effectiveness research with administrative health data in rheumatoid arthritis.Determining early referral criteria for patients with suspected inflammatory arthritis presenting to primary care physicians: a cross-sectional study.Reappraisal of the diagnostic and prognostic value of morning stiffness in arthralgia and early arthritis: results from the Groningen EARC, Leiden EARC, ESPOIR, Leiden EAC and REACH.Serological and Progression Differences of Joint Destruction in the Wrist and the Feet in Rheumatoid Arthritis - A Cross-Sectional Cohort Study.Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study.Studies on ageing and the severity of radiographic joint damage in rheumatoid arthritis.IL2RA is associated with persistence of rheumatoid arthritis.Possibilities for preventive treatment in rheumatoid arthritis? Lessons from experimental animal models of arthritis: a systematic literature review and meta-analysis.cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis.PTGER4 gene variant rs76523431 is a candidate risk factor for radiological joint damage in rheumatoid arthritis patients: a genetic study of six cohorts.Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study.Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trialEfficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritisFactors Contributing to Discordance between the 2011 ACR/EULAR Criteria and Physician Clinical Judgment for the Identification of Remission in Patients with Rheumatoid Arthritis.Access to rheumatologists among patients with newly diagnosed rheumatoid arthritis in a Canadian universal public healthcare system.Psoriasis: to treat or to manage?Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides.Judicious use of biologicals in juvenile idiopathic arthritis.Combination therapy for early rheumatoid arthritis: a treatment holiday perspective.Advances in use of immunomodulatory agents--a rheumatology perspective.Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands.Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial.'The lesser of two evils…' - views of persons with rheumatoid arthritis on medication adherence: a qualitative study.How do general practitioners identify inflammatory arthritis? A cohort analysis of Dutch general practitioner electronic medical records.Diagnostic Delay in Rheumatoid Arthritis: A Qualitative Study of Symptom Interpretation Before the First Visit to the Doctor.Response to methotrexate predicts long-term patient-related outcomes in rheumatoid arthritis.Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients.Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations.Which patients presenting with arthralgia eventually develop rheumatoid arthritis? The current state of the art.Parallel ocular and serologic course in a patient with early Sjogren's syndrome markers.Low-molecular-weight adiponectin is more closely associated with disease activity of rheumatoid arthritis than other adiponectin multimeric forms.Preventing progression from arthralgia to arthritis: targeting the right patients.Autoantibodies to two novel peptides in seronegative and early rheumatoid arthritis.
P2860
Q26738960-F16E79F4-B6B3-46D7-AF94-DC4BD8F71DCDQ26777903-51EEA534-802D-4C3E-90F2-1207F9E603A0Q30839439-C31376C6-FAC5-4D40-8F0C-FE7F6A3B98A9Q30890060-9106AC65-C7C9-4ED3-BD6D-F032CCB24169Q31077662-7973F11F-309A-416D-A4A3-F260E66EFF9DQ33631273-5868FABF-0916-40C2-AEF1-1B074E5AE53EQ35654047-89EBDA88-13A8-4D8D-A770-4AEEC9895FCEQ35759047-C1F3474B-090D-45F2-9EF7-A71822A7C1B6Q35891851-5B80AC23-177F-44D9-9877-87B0A1D877D9Q35910779-EC998515-7169-4DB3-B9A5-30EC7DC3EC82Q35990362-728417C4-9A91-4A88-8DF1-38CD5E62F16EQ36040806-955444A0-0D04-495F-ACFC-812CB52EA6D4Q36092234-3054C1F4-6800-4438-B4B1-3B9545F33735Q36098311-224A8FC7-06DA-426A-BD79-E3C6C2897932Q36251297-4FB3CAA8-E525-4C0C-B600-59773A2DC44EQ36603271-A9B9C6A5-150C-4E69-ADA3-D246A314E259Q36657901-A44EE62C-C01E-4B73-9D09-35C0F16645F5Q37133755-3AEA795F-E299-4555-9EE0-0EAD518705A3Q37404912-DE211C71-DCAF-423C-AC28-E8316F669108Q37552303-CC4AE8D1-4068-42D2-97CB-14987DB9708BQ38210780-60952F15-AF32-4720-A501-06845099E6B1Q38238931-F5982977-C7FF-48BB-ABDC-1099E89AFE9CQ38248905-D82AEB4D-C21C-4893-B02A-A4EE72567403Q38270917-A16CBDBB-9225-485F-9F5C-8D5E247814F8Q38431512-351C1977-4257-42AD-A867-6EE5822F0F32Q38752119-20EC6B7A-43C5-4A47-9C40-633BC647B6D4Q39043798-C9196331-2412-4F30-982C-4664C2323164Q39888893-A00FA010-8550-4AFC-BCA6-9FFFCE284E7DQ40035636-8C8A9E47-C43E-4CE7-AB32-8AF6EAB4F19FQ40126794-DFB81907-F624-4589-AD6A-CE0DBF00E20BQ40859869-A4235D5E-EDEC-4FD3-9E9B-AECE1B2A4CDAQ40884573-3EDE3884-9F9C-4DD9-9201-18C1663A5C0DQ41697121-AA6D47F4-4B06-4F06-B0A4-3B9CADE8DD9CQ41918950-6B251FB5-41E5-4654-A582-5867BB830078Q42273153-D34F9827-EBBD-443B-A459-28FA3BE53708Q46720103-275E8AB5-4C30-4B1B-8A70-44620F555F4AQ47110714-D0142084-BE02-478E-883F-D2DF5D87CC9FQ47401668-4F30DB18-3010-41CD-8A37-216604ED1184Q47423382-CA4CDC1A-E9DA-45CC-998A-60B8552C6CB8Q47821544-8C6A390D-0761-4C16-AC2E-A65C89B84656
P2860
What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
What is the evidence for the p ...... systematic literature review.
@en
type
label
What is the evidence for the p ...... systematic literature review.
@en
prefLabel
What is the evidence for the p ...... systematic literature review.
@en
P2093
P2860
P1476
What is the evidence for the p ...... systematic literature review.
@en
P2093
A H M van der Helm-van Mil
J A B van Nies
J W Schoones
T W J Huizinga
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-203130
P407
P577
2013-04-09T00:00:00Z